Honorary Professor

Kum Kum Khanna

Email: 

Availability

Honorary Professor Kum Kum Khanna is:
Available for supervision

Fields of research

Biological Sciences Oncology and carcinogenesis

Search Professor Kum Kum Khanna’s works on UQ eSpace

190 works between 1995 and 2024
All (190) Journal Article (178) Conference Publication (11) Other Outputs (1)

1 - 20 of 190 works

2024

Journal Article

Targeting chromosomal instability and aneuploidy in cancer

Bhatia, Sugandha, Khanna, Kum Kum and Duijf, Pascal H.G. (2024). Targeting chromosomal instability and aneuploidy in cancer. Trends in Pharmacological Sciences, 45 (3), 210-224. doi: 10.1016/j.tips.2024.01.009

Targeting chromosomal instability and aneuploidy in cancer

2023

Journal Article

COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis

Hancock, Janelle L., Kalimutho, Murugan, Straube, Jasmin, Lim, Malcolm, Gresshoff, Irma, Saunus, Jodi M., Lee, Jason S., Lakhani, Sunil R., Simpson, Kaylene J., Bush, Ashley I., Anderson, Robin L. and Khanna, Kum Kum (2023). COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. Journal of Experimental and Clinical Cancer Research, 42 (1) 90, 1-16. doi: 10.1186/s13046-023-02663-8

COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis

2023

Journal Article

Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma

Raninga, Prahlad V., He, Yaowu, Datta, Keshava K., Lu, Xue, Maheshwari, Uma R., Venkat, Pooja, Mayoh, Chelsea, Gowda, Harsha, Kalimutho, Murugan, Hooper, John D. and Khanna, Kum Kum (2023). Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. Molecular Therapy, 31 (3) ARTN 212011, 729-743. doi: 10.1016/j.ymthe.2022.12.011

Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma

2023

Journal Article

Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice

Rashidieh, Behnam, Bain, Amanda Louise, Tria, Simon Manuel, Sharma, Sowmya, Stewart, Cameron Allan, Simmons, Jacinta Ley, Apaja, Pirjo M., Duijf, Pascal H. G., Finnie, John and Khanna, Kum Kum (2023). Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice. Experimental Hematology and Oncology, 12 (1) 4, 1-4. doi: 10.1186/s40164-022-00365-z

Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice

2022

Conference Publication

Understanding the role of Cep55 in initiation and progression of cancers

Rashidieh, Behnam, Tria, Simon M. and Khanna, Kum Kum (2022). Understanding the role of Cep55 in initiation and progression of cancers. AACR Annual Meeting 2022, New Orleans, LA United States, 8-13 April 2022. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2022-6033

Understanding the role of Cep55 in initiation and progression of cancers

2022

Journal Article

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

Saunus, Jodi M., De Luca, Xavier M., Northwood, Korinne, Raghavendra, Ashwini, Hasson, Alexander, McCart Reed, Amy E., Lim, Malcolm, Lal, Samir, Vargas, A. Cristina, Kutasovic, Jamie R., Dalley, Andrew J., Miranda, Mariska, Kalaw, Emarene, Kalita-de Croft, Priyakshi, Gresshoff, Irma, Al-Ejeh, Fares, Gee, Julia M. W., Ormandy, Chris, Khanna, Kum Kum, Beesley, Jonathan, Chenevix-Trench, Georgia, Green, Andrew R., Rakha, Emad A., Ellis, Ian O., Nicolau, Dan V., Simpson, Peter T. and Lakhani, Sunil R. (2022). Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. npj Breast Cancer, 8 (1) 57, 1-16. doi: 10.1038/s41523-022-00425-x

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

2021

Journal Article

Targeting BRF2 in cancer using repurposed drugs

Rashidieh, Behnam, Molakarimi, Maryam, Mohseni, Ammar, Tria, Simon Manuel, Truong, Hein, Srihari, Sriganesh, Adams, Rachael C., Jones, Mathew, Duijf, Pascal H. G., Kalimutho, Murugan and Khanna, Kum Kum (2021). Targeting BRF2 in cancer using repurposed drugs. Cancers, 13 (15) 3778, 1-28. doi: 10.3390/cancers13153778

Targeting BRF2 in cancer using repurposed drugs

2021

Journal Article

Differential regulation of lacto-/neolacto- glycosphingolipid biosynthesis pathway reveals transcription factors as potential candidates in triple-negative breast cancer

Zeng, Ruichao, Mohamed, Ahmed, Khanna, Kum Kum and Hill, Michelle M. (2021). Differential regulation of lacto-/neolacto- glycosphingolipid biosynthesis pathway reveals transcription factors as potential candidates in triple-negative breast cancer. Cancers, 13 (13) 3330, 1-15. doi: 10.3390/cancers13133330

Differential regulation of lacto-/neolacto- glycosphingolipid biosynthesis pathway reveals transcription factors as potential candidates in triple-negative breast cancer

2021

Journal Article

Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response

McMahon, Kerrie-Ann, Stroud, David A., Gambin, Yann, Tillu, Vikas, Bastiani, Michele, Sierecki, Emma, Polinkovsky, Mark E., Hall, Thomas E., Gomez, Guillermo A., Wu, Yeping, Parat, Marie-Odile, Martel, Nick, Lo, Harriet P., Khanna, Kum Kum, Alexandrov, Kirill, Daly, Roger, Yap, Alpha, Ryan, Michael T. and Parton, Robert G. (2021). Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response. eLife, 10 e61407, 1-35. doi: 10.7554/elife.61407

Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response

2021

Journal Article

WDR62 is required for centriole duplication in spermatogenesis and manchette removal in spermiogenesis

Ho, Uda Y., Feng, Chun-Wei Allen, Yeap, Yvonne Y., Bain, Amanda L., Wei, Zhe, Shohayeb, Belal, Reichelt, Melissa E., Homer, Hayden, Khanna, Kum Kum, Bowles, Josephine and Ng, Dominic C. H. (2021). WDR62 is required for centriole duplication in spermatogenesis and manchette removal in spermiogenesis. Communications Biology, 4 (1) 645, 1-14. doi: 10.1038/s42003-021-02171-5

WDR62 is required for centriole duplication in spermatogenesis and manchette removal in spermiogenesis

2021

Journal Article

CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer

Makhale, Ashwini, Nanayakkara, Devathri, Raninga, Prahlad, Khanna, Kum Kum and Kalimutho, Murugan (2021). CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer. International Journal of Molecular Sciences, 22 (11) ARTN 5782, 5782. doi: 10.3390/ijms22115782

CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer

2020

Journal Article

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Sanij, Elaine, Hannan, Katherine M., Xuan, Jiachen, Yan, Shunfei, Ahern, Jessica E., Trigos, Anna S., Brajanovski, Natalie, Son, Jinbae, Chan, Keefe T., Kondrashova, Olga, Lieschke, Elizabeth, Wakefield, Matthew J., Frank, Daniel, Ellis, Sarah, Cullinane, Carleen, Kang, Jian, Poortinga, Gretchen, Nag, Purba, Deans, Andrew J., Khanna, Kum Kum, Mileshkin, Linda, McArthur, Grant A., Soong, John, Berns, Els M. J. J., Hannan, Ross D., Scott, Clare L., Sheppard, Karen E. and Pearson, Richard B. (2020). CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nature Communications, 11 (1) 2641, 1-18. doi: 10.1038/s41467-020-16393-4

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

2020

Journal Article

Cep55 overexpression promotes genomic instability and tumorigenesis in mice

Sinha, Debottam, Nag, Purba, Nanayakkara, Devathri, Duijf, Pascal H. G., Burgess, Andrew, Raninga, Prahlad, Smits, Veronique A. J., Bain, Amanda L., Subramanian, Goutham, Wall, Meaghan, Finnie, John. W., Kalimutho, Murugan and Khanna, Kum Kum (2020). Cep55 overexpression promotes genomic instability and tumorigenesis in mice. Communications Biology, 3 (1) 593, 1-16. doi: 10.1038/s42003-020-01304-6

Cep55 overexpression promotes genomic instability and tumorigenesis in mice

2020

Journal Article

The implication of the SUMOylation pathway in breast cancer pathogenesis and treatment

Rabellino, Andrea and Khanna, Kum Kum (2020). The implication of the SUMOylation pathway in breast cancer pathogenesis and treatment. Critical Reviews in Biochemistry and Molecular Biology, 55 (1), 54-70. doi: 10.1080/10409238.2020.1738332

The implication of the SUMOylation pathway in breast cancer pathogenesis and treatment

2020

Journal Article

Chromosome arm aneuploidies shape tumour evolution and drug response

Shukla, Ankit, Nguyen, Thu H. M., Moka, Sarat B., Ellis, Jonathan J., Grady, John P., Oey, Harald, Cristino, Alexandre S., Khanna, Kum Kum, Kroese, Dirk P., Krause, Lutz, Dray, Eloise, Fink, J. Lynn and Duijf, Pascal H. G. (2020). Chromosome arm aneuploidies shape tumour evolution and drug response. Nature Communications, 11 (1) 449, 449. doi: 10.1038/s41467-020-14286-0

Chromosome arm aneuploidies shape tumour evolution and drug response

2020

Journal Article

Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer

Raninga, Prahlad V., Lee, Andy C., Sinha, Debottam, Shih, Yu-Yin, Mittal, Deepak, Makhale, Ashwini, Bain, Amanda L., Nanayakarra, Devathri, Tonissen, Kathryn F., Kalimutho, Murugan and Khanna, Kum Kum (2020). Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. International Journal of Cancer, 146 (1), 123-136. doi: 10.1002/ijc.32410

Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer

2020

Journal Article

Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma

Sze, Jun Hui, Raninga, Prahlad V., Nakamura, Kyohei, Casey, Mika, Khanna, Kum Kum, Berners-Price, Susan J., Di Trapani, Giovanna and Tonissen, Kathryn F. (2020). Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma. Redox Biology, 28 101310, 1-12. doi: 10.1016/j.redox.2019.101310

Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma

2020

Journal Article

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

Raninga, Prahlad, Lee, Andy, Sinha, Debottam, Dong, Lan-feng, Datta, Keshava, Lu, Xue, Kalita-de Croft, Priyakshi, Dutt, Mriga, Hill, Michelle M., Pouliot, Normand M., Gowda, Harsha, Kalimutho, Murugan, Neuzil, Jiri and Khanna, Kum Kum (2020). Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics, 10 (12), 5259-5275. doi: 10.7150/thno.42705

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

2019

Journal Article

LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer (vol 8, 73, 2018)

Boulding, T., McCuaig, R. D., Tan, A., Hardy, K., Wu, F., Dunn, J., Kalimutho, M., Sutton, C. R., Forwood, J. K., Bert, A. G., Goodall, G. J., Malik, L., Yip, D., Dahlstrom, J. E., Zafar, A., Khanna, K. K. and Rao, S. (2019). LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer (vol 8, 73, 2018). Scientific Reports, 9 ARTN 18771. doi: 10.1038/s41598-019-55020-1

LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer (vol 8, 73, 2018)

2019

Conference Publication

Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer

Raninga, P., Lee, A., Sinha, D., Shin, Y-Y., Mittal, D., Kalimutho, M. and Khanna, K. K. (2019). Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press.

Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer

Current funding

  • 2024
    Exploitation of immunogenicity of Cep 55 to enhance efficacy of therapy for triple-negative breast cancer
    National Breast Cancer Foundation Investigator Initiated Research Scheme
    Open grant
  • 2024 - 2025
    Targeting the redox niche if triple-negative breast cancer to treat brain metastases
    National Breast Cancer Foundation Investigator Initiated Research Scheme
    Open grant
  • 2024 - 2027
    Targeting metstatic breast cancer by oligonucleotide therapeutics with the FDA lipid nanoparticles (LNP) delivery system.
    National Breast Cancer Foundation Investigator Initiated Research Scheme
    Open grant

Availability

Honorary Professor Kum Kum Khanna is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Functional validation of therapeutic targets for basal breast cancer

    Principal Advisor

  • Doctor Philosophy

    Repurposing FDA-approved drug to treat brain metastatic breast cancer.

    Principal Advisor

  • Doctor Philosophy

    Understanding novel regulators of mitosis and their implication in cancer

    Principal Advisor

Completed supervision

Enquiries

For media enquiries about Honorary Professor Kum Kum Khanna's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au